Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 878657, 7 pages
http://dx.doi.org/10.1155/2012/878657
Research Article

The Immunogenicity of the Tumor-Associated Antigen α-Fetoprotein Is Enhanced by a Fusion with a Transmembrane Domain

1INSERM U948, Biothérapies Hépatiques, CHU Hotel Dieu, 44093 Nantes Cedex, France
2Transgene SA, Boulevard Gonthier d’Andernach, 67405 Illkirch Graffenstaden, France

Received 11 October 2011; Revised 10 November 2011; Accepted 10 November 2011

Academic Editor: Abdel A. Abdel-Rahman

Copyright © 2012 Lucile Tran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Taieb, J. C. Barbare, T. Boussaha et al., “Management of hepatocellular carcinoma. Where are we now? What's next?” Bulletin du Cancer, vol. 96, no. 1, pp. 19–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Zerbini, M. Pilli, C. Ferrari, and G. Missale, “Is there a role for immunotherapy in hepatocellular carcinoma?” Digestive and Liver Disease, vol. 38, no. 4, pp. 221–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. V. N. Evdokimova and L. H. Butterfield, “α-Fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer,” Expert Opinion on Biological Therapy, vol. 8, no. 3, pp. 325–336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. L. H. Butterfield, A. Koh, W. Meng et al., “Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein,” Cancer Research, vol. 59, no. 13, pp. 3134–3142, 1999. View at Google Scholar · View at Scopus
  6. L. H. Butterfield, W. S. Meng, A. Koh et al., “T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein,” The Journal of Immunology, vol. 166, no. 8, pp. 5300–5308, 2001. View at Google Scholar · View at Scopus
  7. L. H. Butterfield, A. Ribas, V. B. Dissette et al., “A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides,” Clinical Cancer Research, vol. 12, no. 9, pp. 2817–2825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. L. H. Butterfield, A. Ribas, W. S. Meng et al., “T-cell responses to HLA-A*0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer,” Clinical Cancer Research, vol. 9, no. 16, part 1, pp. 5902–5908, 2003. View at Google Scholar · View at Scopus
  9. C. M. Vollmer Jr., F. C. Eilber, L. H. Butterfield et al., “α-Fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma,” Cancer Research, vol. 59, no. 13, pp. 3064–3067, 1999. View at Google Scholar · View at Scopus
  10. J. Cany, A. Avril, V. Pichard, D. Aubert, N. Ferry, and S. Conchon, “A transgenic mouse with β-Galactosidase as a fetal liver self-antigen for immunotherapy studies,” Journal of Hepatology, vol. 47, no. 3, pp. 396–403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Engelhorn, J. A. Guevara-Patiño, T. Merghoub et al., “Mechanisms of immunization against cancer using chimeric antigens,” Molecular Therapy, vol. 16, no. 4, pp. 773–781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Quaglino, C. Mastini, A. Amici et al., “A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins,” Cancer Research, vol. 70, no. 7, pp. 2604–2612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Liao, P. Gregor, J. D. Wolchok et al., “Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma,” Cancer Immunity, vol. 6, article 8, 2006. View at Google Scholar · View at Scopus
  14. G. Sutter and B. Moss, “Nonreplicating vaccinia vector efficiently expresses recombinant genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 22, pp. 10847–10851, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. P. M. Arlen, J. L. Gulley, R. A. Madan, J. W. Hodge, and J. Schlom, “Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy,” Critical Reviews in Immunology, vol. 27, no. 5, pp. 451–462, 2007. View at Google Scholar · View at Scopus
  16. B. Acres and J. Y. Bonnefoy, “Clinical development of MVA-based therapeutic cancer vaccines,” Expert Review of Vaccines, vol. 7, no. 7, pp. 889–893, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Gasteiger, W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler, “Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines,” Journal of Virology, vol. 81, no. 21, pp. 11925–11936, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. F. G. Falkner and B. Moss, “Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors,” Journal of Virology, vol. 62, no. 6, pp. 1849–1854, 1988. View at Google Scholar · View at Scopus
  19. J. Cany, B. Barteau, L. Tran et al., “AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice,” Journal of Hepatology, vol. 54, no. 1, pp. 115–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Erbs, A. Findeli, J. Kintz et al., “Modified vaccinia virus Ankara as a vector for suicide gene therapy,” Cancer Gene Therapy, vol. 15, no. 1, pp. 18–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Frimpong-Boateng, N. van Rooijen, and R. Geiben-Lynn, “Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFβ,” PLoS One, vol. 5, no. 8, Article ID e12281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Pilon, M. P. Piechocki, and W. Z. Wei, “Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody,” The Journal of Immunology, vol. 167, no. 6, pp. 3201–3206, 2001. View at Google Scholar · View at Scopus
  23. M. Hareuveni, C. Gautier, M. P. Kieny, D. Wreschner, P. Chambon, and R. Lathe, “Vaccination against tumor cells expressing breast cancer epithelial tumor antigen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 23, pp. 9498–9502, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Hareuveni, D. H. Wreschner, M. P. Kieny et al., “Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA),” Vaccine, vol. 9, no. 9, pp. 618–626, 1991. View at Google Scholar · View at Scopus
  25. V. Racanelli and B. Rehermann, “The liver as an immunological organ,” Hepatology, vol. 43, no. 2, supplement 1, pp. S54–S62, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. He, D. Shen, M. A. O'Donnell, and H. R. Chang, “Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2,” International Journal of Oncology, vol. 20, no. 6, pp. 1305–1311, 2002. View at Google Scholar · View at Scopus
  27. J. Bubenik, “Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours,” Current Cancer Drug Targets, vol. 8, no. 3, pp. 180–186, 2008. View at Publisher · View at Google Scholar · View at Scopus